These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35138060)

  • 21. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
    Hansel K; Zangrilli A; Bianchi L; Peris K; Chiricozzi A; Offidani A; Diotallevi F; Fargnoli MC; Esposito M; Amerio P; Gualdi G; Bianchi L; Stingeni L
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e169-e170. PubMed ID: 33080112
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.
    Yiu ZZ; Warren RB
    Expert Opin Investig Drugs; 2017 Feb; 26(2):243-249. PubMed ID: 28042732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
    Xu S; Gao X; Deng J; Yang J; Pan F
    J Dtsch Dermatol Ges; 2021 Jan; 19(1):47-56. PubMed ID: 33377312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient.
    Hanna S; Youssef P; Lowe P
    Australas J Dermatol; 2022 Feb; 63(1):e63-e66. PubMed ID: 34813085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
    Syed MN; Shin DB; Wan MT; Winthrop KL; Gelfand JM
    J Am Acad Dermatol; 2020 Nov; 83(5):1523-1526. PubMed ID: 32622891
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
    Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
    Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
    Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
    Khatri A; Suleiman AA; Polepally AR; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):378-387. PubMed ID: 31355921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.
    Lin PH; Tsai TF
    Eur J Dermatol; 2021 Apr; 31(2):251-252. PubMed ID: 33875411
    [No Abstract]   [Full Text] [Related]  

  • 38. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risankizumab for the treatment of moderate to severe psoriasis.
    Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
    Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
    [No Abstract]   [Full Text] [Related]  

  • 40. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
    Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
    Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.